BRIEF RESEARCH REPORT article

Front. Immunol.

Sec. Nutritional Immunology

Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1588919

This article is part of the Research TopicElevating Supportive Care Measures for Multiple Myeloma in the Modern EraView all 3 articles

Impact of Pretransplant Vitamin D Deficiency on Immune Recovery and Clinical Outcomes in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

Provisionally accepted
Amany R. KeruakousAmany R. Keruakous1,2*Nabil GhaniNabil Ghani2Shreya DesaiShreya Desai2Christopher TerrellChristopher Terrell2Shahrzad ZamaniShahrzad Zamani3Linda YounLinda Youn4Sindu IskaSindu Iska2Mai KeruakousMai Keruakous5Zhu CuiZhu Cui6
  • 1Augusta University, Augusta, United States
  • 2Georgia Cancer Center, Augusta University, Augusta, Georgia, United States
  • 3Philadelphia College of Osteopathic Medicine (PCOM), Philadelphia, Pennsylvania, United States
  • 4St. Bernard Medical Center, Jonesboro, Arkansas, United States
  • 5Rutgers Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States
  • 6Tufts Medical Center, Boston, Massachusetts, United States

The final, formatted version of the article will be published soon.

Select one of your emails

You have multiple emails registered with Frontiers:

Notify me on publication

Please enter your email address:

If you already have an account, please login

You don't have a Frontiers account ? You can register here

This study examines the impact of pretransplant vitamin D deficiency on immune recovery and clinical outcomes in multiple myeloma patients undergoing autologous stem cell transplantation (ASCT). Given vitamin D's known immunomodulatory effects, the research describes its influence on neutrophil and platelet engraftment, lymphocyte recovery, and overall response rates post-ASCT. By analyzing a retrospective cohort, the study highlights potential associations between vitamin D status and post-transplant immune reconstitution, contributing to understanding vitamin D's role in optimizing treatment strategies for multiple myeloma patients.Multiple myeloma (MM), considered the second most common hematological malignancy, is a plasma cell neoplasm that causes morbidity and mortality through its effects on organs, organ systems, and immunity. Clinical manifestations of MM include renal dysfunction, hypercalcemia, osteolytic bone lesions, anemia (CRAB Criteria), pathological fractures, and immunosuppression. The majority of myeloma patients suffer from long-term immunoparesis, which means suppression of uninvolved immunoglobulins (Igs), and these findings have been reported to be associated with poor prognosis in patients with multiple myeloma (MM).

Keywords: Multiple Myeloma, immunereconstitution, Vitamin D, Post Transplant Outcomes, Supportive Care

Received: 06 Mar 2025; Accepted: 28 May 2025.

Copyright: © 2025 Keruakous, Ghani, Desai, Terrell, Zamani, Youn, Iska, Keruakous and Cui. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Amany R. Keruakous, Augusta University, Augusta, United States

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Supplementary Material